Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: BTG2

Summary for BTG2

Gene information	Gene symbol	BTG2
	Ensembl ID	ENSG00000159388
	Entrez ID	7832
	Gene name	BTG anti-proliferation factor 2
	Synonyms	APRO1\|MGC126063\|MGC126064\|PC3\|TIS21
	Gene type	protein_coding
	UniProtAcc	P78543

Top

Dataset with differentially expressed gene: BTG2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.636793	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.279918	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	0.614435	5.73e-04
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.318859	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.38763	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.262923	2.28e-38
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.487964	1.46e-10
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.478995	3.72e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.334094	1.62e-32
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.650647	8.90e-36
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.636702	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.312321	9.22e-06
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.886504	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Plasma cells	-0.559085	7.25e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.375634	5.91e-05
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	0.754115	1.07e-39
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	0.46809	5.06e-11
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.28165	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.35082	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.480603	2.27e-19
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-1.01399	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.258727	3.67e-21
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.752856	6.48e-39
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.962972	9.99e-09
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.452621	3.39e-02
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	1.13772	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.532791	4.20e-04
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.312906	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.839452	1.93e-12
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.604447	1.39e-32
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.287032	7.82e-05
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	pre	Malignant cells	-0.413389	0.00e+00
GSE158457	PDX cells	Cell line	Acute lymphoblastic leukemia	T-cell acute lymphoblastic leukemia (ALL)	Targeted therapy	dasatinib	NA	Malignant cells	0.255073	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.304345	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.300326	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.383906	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.62394	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.314704	8.70e-25
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.586279	9.40e-22
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.545337	5.23e-10
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	-0.316429	1.93e-13
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	-0.295382	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.404929	2.84e-28
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	0.634164	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD4+ T cells	-0.264323	3.24e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.407625	3.77e-25
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	1.60948	0.00e+00

Top

Expression of BTG2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to BTG2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating BTG2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
BTG2	hsa-miR-6875-3p	99.2237	NM_006763
BTG2	hsa-miR-92a-3p	99.1514	NM_006763
BTG2	hsa-miR-32-5p	99.1514	NM_006763
BTG2	hsa-miR-92b-3p	99.1514	NM_006763
BTG2	hsa-miR-210-5p	98.5703	NM_006763
BTG2	hsa-miR-25-3p	98.4059	NM_006763
BTG2	hsa-miR-367-3p	98.4059	NM_006763
BTG2	hsa-miR-363-3p	98.4059	NM_006763
BTG2	hsa-miR-548ah-5p	97.2253	NM_006763
BTG2	hsa-miR-3609	96.7822	NM_006763
BTG2	hsa-miR-27b-3p	96.6805	NM_006763
BTG2	hsa-miR-27a-3p	96.6805	NM_006763
BTG2	hsa-miR-9985	96.6805	NM_006763
BTG2	hsa-miR-153-5p	96.3111	NM_006763
BTG2	hsa-miR-4709-5p	94.9609	NM_006763
BTG2	hsa-miR-802	93.6712	NM_006763
BTG2	hsa-miR-6515-3p	93.6341	NM_006763
BTG2	hsa-miR-6825-5p	93.2751	NM_006763
BTG2	hsa-miR-7705	92.8486	NM_006763
BTG2	hsa-miR-605-3p	92.2259	NM_006763
BTG2	hsa-miR-4267	92.1435	NM_006763
BTG2	hsa-miR-5682	91.8946	NM_006763
BTG2	hsa-miR-2355-5p	91.7311	NM_006763
BTG2	hsa-miR-7106-3p	91.1767	NM_006763
BTG2	hsa-miR-4251	91.1238	NM_006763
BTG2	hsa-miR-29c-3p	91.0977	NM_006763
BTG2	hsa-miR-29b-3p	91.0977	NM_006763
BTG2	hsa-miR-29a-3p	91.0977	NM_006763
BTG2	hsa-miR-302a-5p	90.8831	NM_006763
BTG2	hsa-miR-513a-5p	90.7032	NM_006763
BTG2	hsa-miR-5011-5p	90.4592	NM_006763
BTG2	hsa-miR-21-5p	90.3437	NM_006763
BTG2	hsa-miR-6852-5p	90.2174	NM_006763
BTG2	hsa-miR-487a-3p	90.083	NM_006763
BTG2	hsa-miR-154-3p	90.083	NM_006763
BTG2	hsa-miR-4786-5p	89.0494	NM_006763
BTG2	hsa-miR-4319	88.7609	NM_006763
BTG2	hsa-miR-218-1-3p	87.9419	NM_006763
BTG2	hsa-miR-559	87.7258	NM_006763
BTG2	hsa-miR-1277-5p	87.5325	NM_006763
BTG2	hsa-miR-4743-3p	87.3636	NM_006763
BTG2	hsa-miR-6838-5p	87.2895	NM_006763
BTG2	hsa-miR-3119	86.7386	NM_006763
BTG2	hsa-miR-548c-5p	86.0478	NM_006763
BTG2	hsa-miR-548ap-5p	86.0478	NM_006763
BTG2	hsa-miR-548ar-5p	86.0478	NM_006763
BTG2	hsa-miR-548d-5p	86.0478	NM_006763
BTG2	hsa-miR-548ay-5p	86.0478	NM_006763
BTG2	hsa-miR-548j-5p	86.0478	NM_006763
BTG2	hsa-miR-548aq-5p	86.0478	NM_006763

Page: 1 2

Top

Motifs and transcription factors (TFs) regulating BTG2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
BTG2	metacluster_167.7	IRF8 (inferredBy_Orthology).
BTG2	taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP	ETV4; GCM1 (directAnnotation).
BTG2	taipale_tf_pairs__GCM1_ELK1_RTGCGGGCGGAAGTN_CAP_2	ELK1; GCM1 (directAnnotation).
BTG2	metacluster_119.2	CCNT2; GATA1; GATA1; GATA1; GATA1; GATA2; GATA2; GATA2; NCOA1; TAL1; TAL1; TAL1; TAL1; ZNF823 (directAnnotation). GATA1; TAL1; TAL1; TAL1; TAL1 (inferredBy_Orthology).
BTG2	tfdimers__MD00145	ELF1; ELF2; ELK1; ELK4; ERF; ERG; ETS1; ETS2; ETV7; FLI1; TCF7L2 (directAnnotation).
BTG2	kznf__ZNF613_Imbeault2017_RP_RCADE	ZNF613 (directAnnotation).
BTG2	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
BTG2	jaspar__MA1125.1	ZNF384 (directAnnotation).
BTG2	tfdimers__MD00095	ELF1; NEUROD1 (directAnnotation).
BTG2	transfac_pro__M05347	NR2C1 (directAnnotation).
BTG2	transfac_pro__M04808	HNF4A (directAnnotation).
BTG2	metacluster_131.11	ZNF746 (directAnnotation).
BTG2	transfac_pro__M05706	ZNF20 (directAnnotation).
BTG2	transfac_pro__M06554	ZNF483 (directAnnotation).
BTG2	metacluster_21.4	HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
BTG2	transfac_pro__M06468	ZNF808 (directAnnotation).
BTG2	transfac_pro__M06721	ZKSCAN7 (directAnnotation).
BTG2	transfac_pro__M06564	ZNF578 (directAnnotation).
BTG2	swissregulon__hs__HSF2	HSF2 (directAnnotation).
BTG2	transfac_pro__M06157	ZNF445 (directAnnotation).
BTG2	transfac_pro__M07479	ZNF35 (directAnnotation).
BTG2	transfac_pro__M05977	ZNF257 (directAnnotation).
BTG2	transfac_pro__M06990	ZNF236 (directAnnotation).
BTG2	metacluster_21.5	HOXB2; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4 (directAnnotation). HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4; HSF4; HSF5; HSF5; HSF5; HSF5; HSFX1; HSFX1; HSFX1; HSFX1; HSFX2; HSFX2; HSFX2; HSFX2; HSFX3; HSFX3; HSFX3; HSFX3; HSFX4; HSFX4; HSFX4; HSFX4; HSFY1; HSFY1; HSFY1; HSFY1; HSFY2; HSFY2; HSFY2; HSFY2 (inferredBy_Orthology).
BTG2	metacluster_56.4	HSF1; HSF2; HSF2; HSF4 (directAnnotation).
BTG2	jaspar__MA1933.1	SREBF2 (directAnnotation).
BTG2	transfac_pro__M00691	ATF1 (directAnnotation).
BTG2	metacluster_155.13	ZNF135 (directAnnotation).
BTG2	taipale_tf_pairs__GCM1_CEBPB_ATRSGGGNNNNTTRCGYAAN_CAP_repr	CEBPB; GCM1 (directAnnotation).
BTG2	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
BTG2	metacluster_141.4	GLIS2 (directAnnotation).
BTG2	cisbp__M00341	PAX6 (directAnnotation).
BTG2	taipale_cyt_meth__IRF6_ACCGAWACY_FL_meth	IRF6 (directAnnotation).
BTG2	tfdimers__MD00476	BACH1; BACH2; FOXG1; FOXO1; MAF; MAFB; MAFF; MAFG; MAFK; NFE2; NFE2L1; NFE2L2; NFE2L3 (directAnnotation).
BTG2	transfac_pro__M12556	ETV4 (directAnnotation).
BTG2	metacluster_141.6	MZF1; TAF1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZNF597 (directAnnotation). TAF1; TAF1L (inferredBy_Orthology).
BTG2	metacluster_31.3	ZSCAN20; ZSCAN29 (directAnnotation).
BTG2	taipale_tf_pairs__GCM1_ETV7_NTRNGGGCGGAAGNNNTTCCNNN_CAP_repr	ETV7; GCM1 (directAnnotation).
BTG2	transfac_pro__M06688	ZKSCAN7 (directAnnotation).
BTG2	transfac_pro__M06750	ZNF510 (directAnnotation).
BTG2	jaspar__MA1563.2	SOX18 (directAnnotation).
BTG2	metacluster_177.7	ZBTB18; ZBTB18; ZBTB18; ZBTB42 (directAnnotation).
BTG2	transfac_pro__M12441	ZNF281 (inferredBy_Orthology).
BTG2	kznf__ZNF669_Najafabadi2015_ChIP-seq	ZNF669 (directAnnotation).
BTG2	taipale_tf_pairs__GCM1_FOXI1_NTGTTGATRNGGGN_CAP_repr	FOXI1; GCM1 (directAnnotation).
BTG2	transfac_pro__M07260	IKZF1 (directAnnotation).
BTG2	hocomoco__PATZ1_HUMAN.H11MO.1.C	PATZ1 (directAnnotation).
BTG2	transfac_pro__M07270	TEAD4 (directAnnotation).
BTG2	transfac_pro__M06907	ZFP3 (inferredBy_Orthology).
BTG2	metacluster_177.5	MSC; MYF6 (directAnnotation). MESP1; MESP2; MSGN1 (inferredBy_Orthology).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."